DB
ADAP

Danske Bank’s Adaptimmune Therapeutics ADAP Stock Holding History

Danske Bank’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed – – 1567
2025
Q3 		$0 Hold
1
– – ﹤0.01% 1490
2025
Q2 		$0 Hold
1
– – ﹤0.01% 1525
2025
Q1 		$0 Hold
1
– – ﹤0.01% 1373
2024
Q4 		$1 Hold
1
– – ﹤0.01% 1388
2024
Q3 		$1 Buy
+1
New +$1 ﹤0.01% 1581

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Danske Bank's ADAP Position: Q4 2025 in Review

Danske Bank sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 1 share.

Danske Bank first reported a position in ADAP in Q3 2024 and held it in 5 quarters. The position peaked at $1 in Q4 2024. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Danske Bank reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Danske Bank sold 1 Adaptimmune Therapeutics share in Q4 2025.
  • Danske Bank first reported a position in Adaptimmune Therapeutics in Q3 2024 and held it in 5 quarters.
  • Danske Bank's Adaptimmune Therapeutics position peaked at $1 in Q4 2024.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Danske Bank's 13F filing for Q4 2025, filed 2 Feb 2026.